drugset / Trial / NCT00434850
Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes
Phase 2
Completed
14 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
NaSingle-groupOpen-labelTreatment
Summary
Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to assess the safety and efficacy of deoxyspergualin (DSG), an immunosuppressant drug, on post-transplant islet function in people with type 1 diabetes who have not responded to intensive insulin therapy.
Timeline
- Start
- 2006-10
- Primary completion
- 2011-09
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic Pancreatic Islet Cells | Cell therapy | — | Other |
| Subject | Deoxyspergualin | Unknown | — | Intravenous |
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | — |
| Background | Basiliximab | Monoclonal antibody | — | — |
| Background | Daclizumab | Monoclonal antibody | — | — |
| Background | Etanercept | Protein / enzyme biologic | — | — |
| Background | Sirolimus | Small molecule | — | — |
| Background | Tacrolimus | Small molecule | — | — |